Arrhythmia Monitoring Devices Market Worth $8.41 Billion by 2025: Grand View Research, Inc.
SAN FRANCISCO, March 20, 2019 /PRNewswire/ --The global arrhythmia monitoring devices market size is expected to reach USD 8.41 billion in 2025with aCAGR of 6.8% during the forecast period, according to a new report by Grand View Research, Inc. Continuous R&D activities in the field of cardiac monitoring are leading to technological expansion. This, in turn, is positively influencing the growth of the arrhythmia monitoring devices market. Wearable diagnostic patch by iRhythm Technologies, Inc., Zio, has led to symptomatic arrhythmia monitoring, which is superior in comparison to conventional Holter monitors.
Key suggestions from the report:
The arrhythmia monitoring devices market is highly competitive and is rapidly evolving with numerous potential market players
Holter monitors dominated the market in terms of revenue in 2017. On the other hand, mobile cardiac telemetry is expected to witness the fastest growth rate during the forecast period
Atrial fibrillation dominated the market in terms of revenue in 2017. The growth in the number of untreated cases of arrhythmias are leading to increasing need for advanced cardiac monitoring devices
Heightened adoption of sophisticated technologies has led to the expansion of the market. Kardia Mobile by AliveCor captures ECG in 30 seconds projecting the heart rhythm for conditions such as atrial fibrillation
The hospitals and clinics segment held the largest share in the market in 2017. On the other hand, diagnostic centers are likely to experience the fastest growth over the forecast period
North America commanded the leading share in the market in 2017 due to faster regulatory approvals for innovative devices and procedures
AliveCor, Inc.; Applied Cardiac Systems; BioTelemetry, Inc.; BIOTRONIK; Fukuda Denshi Co., Ltd.; GE Healthcare; iRhythm; Medi-Lynx; St. Jude Medical (Abbott); Medtronic; Nihon Kohden Corporation; Nuubo; and Spacelabs Healthcare are some of the key players operating in this market.
Big pharma and medical device companies are heavily investing in R&D to perform a detailed mapping of cardiac arrhythmia. In February 2018, Medtronic received FDA clearance for the first non-invasive cardiac mapping system, CardioInsight. It includes wearable 252-electrode sensor vest that creates 3D electroanatomic maps of heart by combining data from a cardiac computed tomography scan with ECG signals collected from the chest region.
In addition to these technologies, emergence and advancements in mobile cardiac telemetry are leading to further progress of the overall market. In October 2017, Abbott received FDA clearance for Confirm Rx, a smartphone-compatible implantable cardiac monitor indicated for arrhythmia diagnosis. Boston Scientific announced its FDA approval for Resonate, a line of cardiac resynchronization therapy defibrillator and cardioverter defibrillator systems for the cardiac management.
Grand View Research has segmented the global arrhythmia monitoring devices market based on type, application, end use, and region:
Arrhythmia Monitoring Devices Type Outlook (Revenue, USD Million, 2014 - 2025)
Manual Resuscitators Market ? The global manual resuscitator market size was valued at USD 363 million in 2015.
Breast Biopsy Device Market ? The Breast Biopsy Device Market size was estimated to be USD 372.9 million in 2015. It is a diagnostic procedure that involves the removal of tissue or fluid from a suspicious area.
Cardiovascular Devices Market ? The global cardiovascular devices market was valued over 33 billion in 2015 and is projected to grow at a CAGR of 6.6% over the forecast period.
Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: +1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected]
bluebird bio, Inc. today announced that it received a notice (the "notice") on April 24, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December...
Repare Therapeutics Inc. ("Repare" or the "Company") , a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company's upcoming annual...
This program will support individuals in Putnam County with Opioid Use Disorder and co-occurring substance use and mental health conditions through peer support and harm reduction for the broader Putnam County community. A...
Life Time continues its growth in Texas with two new athletic country clubs opening in the coming months. Located in Irving, Life Time Las Colinas opens April 26. Later this summer, the nearby Life Time Westlake will debut. A waitlist is now open....
Grossman Law Offices, with its principal office in Dallas, TX, expresses concern and support for Eric Elliott and his family following a truck accident that occurred on February 20, 2024, just before 4:45 p.m. along U.S. Highway 67 in Johnson County,...
Boehringer Ingelheim, the largest animal health company in Georgia and its NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) product, and the Atlanta Braves Foundation, the non-profit arm of the Atlanta Braves, are proud to...